ImmunityBio (IBRX) Common Equity (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Common Equity data on file, last reported at -$870.0 million in Q1 2026.

• On a quarterly basis, Common Equity fell 47.34% year-over-year to -$870.0 million in Q1 2026; TTM through Mar 2026 was -$870.0 million, a 47.34% decrease from a year earlier, with the FY2025 full-year figure at -$500.5 million, down 2.53% from the prior year.
• Common Equity for Q1 2026 stood at -$870.0 million, down from -$500.5 million in the prior quarter.
• Over the last five years, Common Equity for IBRX reached as high as $100000.0 in Q3 2024 and fell as low as -$870.0 million in Q1 2026.
• Historically, Common Equity has averaged -$514.3 million across 5 years, with a median of -$524.3 million in 2025.
• Across the five-year window, Common Equity soared 100.02% in 2024 and tumbled 524419.0% in 2025, its largest moves.
• Year by year, Common Equity stood at -$449.8 million in 2022, then sank by 30.26% to -$585.9 million in 2023, then gained by 16.69% to -$488.1 million in 2024, then decreased by 2.53% to -$500.5 million in 2025, then tumbled by 73.84% to -$870.0 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$870.0 million in Q1 2026, -$500.5 million in Q4 2025, and -$524.3 million in Q3 2025.